Low-dose Chemotherapy Combine With Tyrosine Kinase Inhibitor to Treat ph+ Acute Lymphoblastic Leukemia Patients

NCT02690922 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

40

Enrollment

OTHER

Sponsor class

Conditions

ph+ Acute Lymphoblastic Leukemia

Interventions

DRUG: Dasatinib
DRUG: prednisone
DRUG: dexamethasone
DRUG: methotrexate

Sponsor

Tongji Hospital